Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q2 2024 Earnings Presentation

18 slides from Day One Biopharmaceuticals's earnings presentation, Jul 30, 2024

  1. Slide 1: Second Quarter 2024 Financial Results and Corporate Progress

    Second Quarter 2024 Financial Results and Corporate Progress July 2024 Click to add text Nasdaq: DAWN

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc

  3. Slide 3: Agenda & Day One Participants

    Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM (tovorafenib) Commercial Performance Lauren Merendino (Chief Commercial Officer) Portfolio Expansion & Updates Sam Blackman (Co-Founder & Head of R&D) Second Quarter 2024 Financial Performance Charles York

  4. Slide 4: Opening Remarks

    Opening Remarks Jeremy Bender Chief Executive Officer

  5. Slide 5: Executing On Our Priorities As A Commercial-Stage Company

    Executing On Our Priorities As A Commercial-Stage Company 1 Represents cash, cash equivalents and short-term investments as of June 30, 2024. OJEMDA Launch Strong start with $8.2M in net product revenue in the initial 8 weeks on market Commercial Execution Strong cadence of new patient starts and ra

  6. Slide 6: OJEMDA (tovorafenib) Commercial Performance

    OJEMDATM (tovorafenib) Commercial Performance Lauren Merendino Chief Commercial Officer

  7. Slide 7: Robust Q2 Performance Driven by Excellent Execution & Strong Patient Demand

    Robust Q2 Performance Driven by Excellent Execution & Strong Patient Demand pLGG, pediatric low-grade glioma Q2 OJEMDA Net Revenue $8.2M ~75% Patient Demand ~25% Inventory Launch Execution Excellence Accelerated Customer Engagement Live engagements with >90% of ~200 target accounts $6.1M $2.1M Payer

  8. Slide 8: Patient Demand Driven By Both EAP Transition Patients and New Patient Starts

    Patient Demand Driven By Both EAP Transition Patients and New Patient Starts * Includes US patients on paid drug and commercial free drug programs. Does not include patients not yet transitioned from EAP. Rapid transition of patients on Early Access Program (EAP) to commercial drug Strong new patien

  9. Slide 9: Coverage Approval Rates are High Across Commercial and Medicaid Payers

    Despite Limited Published Coverage To Date, Coverage Approval Rates are High Across both Commercial and Medicaid Payers 59% Commercial Patients 38% Medicaid Patients Commercial Reported Coverage1 Percent of Covered Lives Medicaid Reported Coverage2 Percent of Covered Lives 1Breakaway Partners LLC –

  10. Slide 10: Well-Positioned For Commercial Execution And Sustained Growth

    Well-Positioned For Commercial Execution And Sustained Growth Continuing Launch Trajectory Increase breadth & depth of prescribers Establish OJEMDA in the 2nd line Solidify payer coverage policies

  11. Slide 11: Portfolio Expansion and Updates

    Portfolio Expansion and Updates Sam Blackman Co-Founder & Head of R&D

  12. Slide 12: DAY301: Next Generation ADC Targeting PTK7

    DAY301: Next Generation ADC Targeting PTK7 1 Cho BC, et al. Ann Oncol. (34; Suppl 2): S460-S461, 2023. PTK7: Clinically-Validated ADC Target DAY301: Potential First-in-Class Asset Substantial Development and Potential Commercial Opportunities for DAY301 Anti-tumor activity of anti-PTK7 ADC demonstra

  13. Slide 13: DAY301: Potential First-In-Class Asset

    DAY301: Potential First-In-Class Asset 1) Damelin M, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017. HNSTD, Highest Non-Severely Toxic Dose; P-gp, P-glycoprotein. DAY301 has been designed to maximize therape

  14. Slide 14: DAY301-001: Initial Phase 1/2a Clinical Trial Design

    DAY301-001: Initial Phase 1/2a Clinical Trial Design DL, Dose Level; RD, Recommended Dose; BOIN, Bayesian Optimal Interval; HNSCC, Head and Neck Squamous Cell Carcinoma; SCLC, Small Cell Lung Cancer; SCC, Squamous-Cell Carcinoma; NSCLC, Non-Small Cell Lung Cancer Phase 1a: Monotherapy Dose Escalatio

  15. Slide 15: Our Pipeline

    pLGG, pediatric low-grade glioma. 1 OJEMDA has received accelerated approval by the U.S. Food and Drug Administration. 2 FIREFLY-1 is an open-label, pivotal Phase 2 trial. 3License agreement with Ipsen to commercialize OJEMDA (tovorafenib) outside the U.S. DAY301 is a license agreement with MabCare

  16. Slide 16: Second Quarter 2024 Financial Performance

    Second Quarter 2024 Financial Performance Charles York Chief Operating Officer and Chief Financial Officer

  17. Slide 17: Second Quarter 2024 Financial Results

    Second Quarter 2024 Financial Results All financial information is unaudited. 1 Includes stock-based compensation expense of $4.7 million and $9.4 million for the three and six months ended 6/30/24, and $3.4 million and $6.8 million for the three and six months ended 6/30/23, respectively. 2 Include

  18. Slide 18: Thank You

    Thank You Click to add text Nasdaq: DAWN

Day One Biopharmaceuticals — Q2 2024 Earnings Presentation on 6ix